Drug intelligence / Profile preview

FWB2114

Development stage: Preclinical
Lead developer: Forward Pharmaceuticals Co., Ltd.

Overview

FWB2114 is an investigational biologic therapeutic being developed by Forward Pharmaceuticals Co., Ltd. As of 2024, the asset is in the IND-enabling phase of development. The specific molecular target of FWB2114 is currently undisclosed by the sponsor, which describes it only as a "New Target." The program is part of Forward Pharmaceuticals' broader pipeline of innovative biologics, which includes antibody-drug conjugates (ADCs) and monoclonal antibodies, although the exact modality within the biologic category for FWB2114 has not been specified.

Beyond the preview

Go deeper on FWB2114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FWB2114.

Explore the full profile